Aurobindo Pharma Ltd.

NSE: AUROPHARMA BSE: 524804 SECTOR: Pharmaceuticals & Drugs  88k   854   168

608.80
-8.05 (-1.31%)
NSE: Today, 03:59 PM

Price Summary

Today's High

₹ 618.95

Today's Low

₹ 594

52 Week High

₹ 1063.9

52 Week Low

₹ 590.1

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

35671.94 Cr.

Enterprise Value

39238.86 Cr.

No. of Shares

58.59 Cr.

P/E

17.61

P/B

2.2

Face Value

₹ 1

Div. Yield

0.65 %

Book Value (TTM)

₹  277.3

CASH

386.18 Cr.

DEBT

3953.1 Cr.

Promoter Holding

51.83 %

EPS (TTM)

₹  34.57

Sales Growth

18.35%

ROE

21.49 %

ROCE

23.03%

Profit Growth

65.86 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Aurobindo Pharma Ltd.

Molnaflu Imdur Betaloc Seloken Ramace Plendil RHINOCORT Prostodin MERONEM XyloCaine SensorCaine Iressa Casodex CRESTOR

Index Presence

The company is present in 24 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year18.35%
3 Year15.5%
5 Year11.54%

Profit Growth

1 Year65.86%
3 Year19.75%
5 Year13.86%

ROE%

1 Year21.49%
3 Year17.07%
5 Year18.64%

ROCE %

1 Year23.03%
3 Year17.96%
5 Year18.53%

Debt/Equity

0.2482

Price to Cash Flow

11.91

Interest Cover Ratio

147.199790794979

CFO/PAT (5 Yr. Avg.)

0.906986218815525

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2021 51.83 22.97
Sep 2021 51.83 22.98
Jun 2021 51.83 20.66
Mar 2021 51.94 22.81
Dec 2020 51.94 9.27
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 19.74975119747% for the Past 3 years.
  • The company has shown a good revenue growth of 15.4994190599584% for the Past 3 years.
  • Company has a healthy Interest coverage ratio of 147.199790794979.
  • The Company has been maintaining an effective average operating margins of 23.162464190892% in the last 5 years.
  • Company’s PEG ratio is 0.267379891350698.

 Limitations

  • Promoter pledging is high as 22.97%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021
Net Sales 4548.5 3710.86 4114.03 2893.75 2883.18
Total Expenditure 3340.98 2737.11 3138 2482.94 2543.45
Operating Profit 1207.52 973.75 976.03 410.81 339.73
Other Income 43.17 164.97 267.42 43.95 82.37
Interest 6.45 5.84 5.93 5.06 3.44
Depreciation 121.25 120.63 124.07 114.65 98.18
Exceptional Items 0 0 0 0 0
Profit Before Tax 1122.99 1012.25 1113.45 335.05 320.48
Tax 326.06 271.74 240.87 119.98 122.8
Profit After Tax 796.93 740.51 872.58 215.07 197.68
Adjusted EPS (Rs) 13.6 12.64 14.89 3.67 3.37

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Net Sales 9607.05 10269.9 12257.89 13370.77 15823.68
Total Expenditure 7233.1 7599.89 9848.6 10672.9 11703.85
Operating Profit 2373.95 2670.01 2409.29 2697.87 4119.83
Other Income 135.95 80.65 199.22 388.79 589.86
Interest 45.16 52.89 230.86 243.28 28.68
Depreciation 286.17 354.83 413.03 473.33 488
Exceptional Items 0 0 0 0 0
Profit Before Tax 2178.57 2342.94 1964.62 2370.05 4193.01
Tax 471.81 530.17 434.89 493.17 1080.1
Net Profit 1706.76 1812.77 1529.73 1876.88 3112.91
Adjusted EPS (Rs.) 29.13 30.94 26.11 32.03 53.13

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Equity and Liabilities
Share Capital 58.59 58.59 58.59 58.59 58.59
Total Reserves 8377.59 9923.99 11292.03 12993.91 15866.02
Borrowings 118.9 0 0 0 0
Other N/C liabilities 20.79 57.08 53.64 138.86 507.8
Current liabilities 4446.97 5754.18 6736.46 6372.25 6756.58
Total Liabilities 13022.84 15793.84 18140.72 19563.61 23188.99
Assets
Net Block 3211.62 3392.97 4149.7 4417.8 4472.07
Capital WIP 878.31 1100.23 750.07 814.85 719.02
Intangible WIP 28.67 43.75 38.94 0 15.87
Investments 1681.93 1967.48 2339.04 2527.39 4880.89
Loans & Advances 233.25 207.66 402.93 444.9 664.23
Other N/C Assets 85.71 100.55 51.7 70.37 59.05
Current Assets 6903.35 8981.2 10408.34 11288.3 12377.86
Total Assets 13022.84 15793.84 18140.72 19563.61 23188.99
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Profit from operations 2178.57 2342.94 1964.62 2370.05 4193.01
Adjustment 303.9 329.16 458.99 414.2 53.15
Changes in Assets & Liabilities 457.02 -1219.73 -1411.6 -204.18 -624.9
Tax Paid -482.29 -529.97 -482.12 -378.69 -626.85
Operating Cash Flow 2457.2 922.4 529.89 2201.38 2994.41
Investing Cash Flow -1542.05 -990.6 -1300.54 -948.08 -2650.24
Financing Cash Flow -1328.99 439.69 599.4 -1254.65 -27.94
Net Cash Flow -413.84 371.49 -171.25 -1.35 316.23

Corporate Actions

Investors Details

PARTICULARS Dec 2020% Mar 2021% Jun 2021% Sep 2021% Dec 2021%
Promoters 51.94 51.94 51.83 51.83 51.83
rpr sons advisors ... 33.51 33.51 33.51 33.51 33.51
k nityananda reddy 4.33 4.33 - 4.33 4.33
k nityananda reddy - - 4.33 - -
kambam kirthi reddy 3.49 - - - -
kirthi reddy kambam - 3.49 3.49 3.49 3.49
venkata ramprasad ... 3.07 3.07 3.07 3.07 3.07
axis clinicals lim... 0.11 0.11 0.11 0.11 0.11
axis clinicals lim... 2.85 2.85 2.85 2.85 2.85
m sivakumaran 2.47 2.47 2.47 2.47 2.47
kambam spoorthi - 1.30 1.19 1.19 1.19
k spoorthi 1.30 - - - -
k rajeswari 0.31 - - - -
rajeswari kambam - 0.31 - - -
kottamanchi rajes... - - 0.31 0.31 0.31
m sumanth kumar re... 0.27 0.27 0.27 0.27 0.27
trident chemphar l... 0.13 0.13 0.13 0.13 0.13
prasada reddy kamb... 0.05 0.05 0.05 0.05 0.05
penaka neha reddy 0.02 0.02 0.02 - -
suneela rani penaka - - - 0.02 0.02
PARTICULARS Dec 2020% Mar 2021% Jun 2021% Sep 2021% Dec 2021%
Investors 48.06 48.06 48.17 48.17 48.17
hdfc trustee co lt... - 4.05 - - -
hdfc trustee compa... - - - - -
life insurance cor... - 1.91 3.46 4.34 5.33
hdfc trustee compa... 5.30 - - - -
hdfc trustee compa... - - - - 3.59
hdfc trustee compa... - - 3.40 - -
qualified institut... - - 1.95 - -
nippon life india ... - - - - 1.39
nippon life india ... 1.19 1.11 1.32 - -
reliance capital t... - - - - -
bnp paribas arbitr... - 1.26 - - -
nippon life india ... - - - 1.26 -
bnp paribas arbitr... 1.21 - 1.22 1.22 1.15
reliance capital t... - - - - -
saudi arabian mone... - - 1.03 - -
icici prudential l... - 1.01 - - -
iepf 0.12 0.12 0.12 0.13 0.13

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Aurobindo Pharma informs about newspaper clippings13 Jan 2022, 12:42PM Aurobindo Pharma’s arm expands marketing, distribution agreement with Orion Corporation11 Jan 2022, 12:05PM Aurobindo Pharma launches COVID-19 drug Molnupiravir in India6 Jan 2022, 11:28AM Aurobindo Pharma to produce generic Molnupiravir at domestic manufacturing facilities 29 Dec 2021, 12:07PM Aurobindo Pharma gets DCGI’s permission to manufacture, distribute generic version of Molnupiravir29 Dec 2021, 9:40AM Aurobindo Pharma’s unit recalls 7,296 containers of Carvedilol tablets in US market6 Dec 2021, 11:57AM Aurobindo Pharma informs about newspaper publication29 Nov 2021, 2:39PM Aurobindo Pharma informs about disclosure10 Nov 2021, 10:33AM Aurobindo Pharma reports 14% fall in Q2 consolidated net profit9 Nov 2021, 11:39AM Aurobindo Pharma informs about disclosure6 Nov 2021, 9:49AM Aurobindo Pharma informs about clarification5 Oct 2021, 3:39PM Aurobindo Pharma’s unit recalls 2,820 bottles of Metoprolol tartrate tablets in US market4 Oct 2021, 12:23PM Aurobindo Pharma informs about analyst meet14 Sep 2021, 12:41PM Aurobindo Pharma informs about press release27 Aug 2021, 10:09AM Aurobindo Pharma’s arm receives USFDA’s approval for Cyclophosphamide Injection27 Aug 2021, 9:59AM Aurobindo Pharma terminates agreement with Cronus Pharma21 Aug 2021, 9:41AM Aurobindo Pharma informs about record date13 Aug 2021, 3:36PM Aurobindo Pharma reports marginal fall in Q1 consolidated net profit13 Aug 2021, 10:59AM Aurobindo Pharma informs about newspaper publication5 Aug 2021, 4:31PM Aurobindo Pharma informs about closure of trading window28 Jun 2021, 11:36AM Aurobindo Pharma informs about disclosure25 Jun 2021, 4:47PM Aurobindo Pharma informs about earnings call trascript11 Jun 2021, 2:58PM Aurobindo Pharma informs about newspaper publication11 Jun 2021, 2:56PM Aurobindo Pharma informs about reappointment of executive directors31 May 2021, 4:16PM Aurobindo Pharma reports 7% fall in Q4 consolidated net profit31 May 2021, 3:00PM Aurobindo Pharma informs about annual secretarial compliance report18 May 2021, 3:56PM Aurobindo Pharma informs about transcript of earnings call25 Feb 2021, 11:19AM Aurobindo Pharma inks pact to invest in two solar power companies24 Feb 2021, 9:09AM Aurobindo Pharma gets USFDA’s final nod to manufacture, market Droxidopa Capsules19 Feb 2021, 11:47AM Aurobindo Pharma’s unit recalling 3,094 cartons of Acetaminophen injection15 Feb 2021, 10:57AM Aurobindo Pharma informs about analyst meet9 Feb 2021, 12:16PM Aurobindo Pharma gets nod for promotion of manufacturing critical bulk drugs23 Jan 2021, 10:05AM Aurobindo Pharma enters into exclusive license agreement with COVAXX24 Dec 2020, 8:55AM Aurobindo Pharma informs about press release9 Dec 2020, 10:30AM Aurobindo Pharma gets USFDA’s nod for Dexmedetomidine HCL in 0.9% Sodium Chloride Injection9 Dec 2020, 10:20AM Aurobindo Pharma’s arms ink pact with affiliate of New Mountain Capital LLC, NY, Jarrow Formulas Inc1 Dec 2020, 9:31AM Aurobindo Pharma gets nod to transfer business undertaking of Auronext Pharma 12 Nov 2020, 9:37AM Aurobindo Pharma completes acquisition of MViyeS Pharma Ventures9 Nov 2020, 9:03AM Aurobindo Pharma informs about acquisition7 Nov 2020, 12:32PM Aurobindo Pharma signs definitive agreement to sell Natrol to New Mountain Capital26 Oct 2020, 11:56AM Aurobindo Pharma gets USFDA’s approval for Acetaminophen Injection 22 Oct 2020, 12:45PM Aurobindo Pharma’s arm receives warning letter from USFDA for New Jersey facility22 Oct 2020, 11:17AM Aurobindo Pharma to acquire entire stake in MViyeS19 Oct 2020, 11:59AM Aurobindo Pharma collaborates with CSIR to develop COVID-19 vaccine 16 Sep 2020, 8:50AM DBT- BIRAC supports Aurobindo Pharma’s COVID-19 vaccine development 15 Sep 2020, 4:34PM Aurobindo Pharma reports 23% rise in Q1 consolidated net profit13 Aug 2020, 11:56AM Aurobindo Pharma working on developing several viral vaccines including one for COVID-197 Aug 2020, 1:22PM Aurobindo Pharma informs about disclosure 10 Jul 2020, 3:27PM Aurobindo Pharma developing range of products in US, EU markets25 Jun 2020, 4:15PM Aurobindo Pharma planning to launch 50-60 new products in US in FY21 22 Jun 2020, 5:03PM

Aurobindo Pharma Stock Price Analysis and Quick Research Report. Is Aurobindo Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Aurobindo Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 2994.41 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Aurobindo Pharma has a Debt to Equity ratio of 0.2482 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Aurobindo Pharma , the EPS growth was 65.8555688163335 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Aurobindo Pharma has OPM of 26.0358525956035 % which is a good sign for profitability.
     
  • ROE: Aurobindo Pharma have a healthy ROE of 21.4853923751225 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Aurobindo Pharma

X